Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Winston Salem, North Carolina 27157


Purpose:

This is a research study whose purpose is to test the effectiveness of etanercept (Enbrel) in the treatment of moderate to severe lichen planus. No studies have been done on the effectiveness of etanercept in lichen planus, although etanercept has been tested and used on other medical conditions. Etanercept has not been FDA approved for the treatment of lichen planus.


Study summary:

Lichen planus is a chronic, inflammatory skin disease which can be particularly difficult to treat. The exact cause of lichen planus is not clear, but a number of studies suggest that immune system cells called T lymphocytes play a role through abnormally increased activity. Etanercept is a drug which helps to maintain proper T lymphocyte activity and has been FDA approved for the treatment of psoriasis, another skin condition known to be caused by T cells with abnormally increased activity. There is no known cure for lichen planus. We hope to learn if etanercept represents an effective and safe treatment for lichen planus. This research study is looking for 64 people with lichen planus. The study will be conducted at 12 sites across the United States. Approximately 5 subjects will be enrolled at this site.


Criteria:

Inclusion Criteria: - At least 18 years of age. - Must carry a diagnosis of lichen planus as determined by either a skin or mucosal biopsy - Patients must have a score of 3 or greater (moderate-severe) on the PGA for cutaneous or mucosal disease - Patient must be considered appropriate for systemic therapy based upon fulfilling one of the following criteria: - inability to maintain weight due to pain with eating, chewing, or swallowing; - dyspareunia or dysuria due to genital lesions; - itch/pain of sufficient severity that activities of daily living are significantly affected—this includes sleeping, cleansing oneself, performing one's occupation. Exclusion Criteria: - Known HIV-positive status, any other immuno-suppressive disease, or inability to practice safe sex during the length of the study - Subject has been diagnosed with a malignancy within the past 5 years except for successfully treated non-melanoma skin cancer or in-situ cervical carcinoma. - Subject has signs or symptoms of a lymphoproliferative disease. - Other skin or mucosal disease that might interfere with lichen planus assessments, including signs of squamous cell carcinoma. - Lichen planus variants including hypertrophic, atrophic, follicular (including lichen planopilaris), and bullous cutaneous forms.


NCT ID:

NCT00691106


Primary Contact:

Principal Investigator
Joseph Jorizzo, MD
Wake Forest University


Backup Contact:

N/A


Location Contact:

Winston Salem, North Carolina 27157
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.